FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197340014> ?p ?o ?g. }

• W3197340014 endingPage "S317" @default.
• W3197340014 startingPage "S317" @default.
• W3197340014 abstract "Objective: To evaluate how treatment regimens in informCLL aligned with NCCN Guidelines®-recommended regimens for CLL/SLL. Patients: Patients receiving approved CLL treatment were categorized by del(17p)/TP53 mutation status, line of therapy, and age/comorbidity. Significant comorbidities (SC) were defined as Charlson Comorbidity Index (CCI) ≥3. Age/comorbidity groups for patients without del(17p)/TP53mut: frail (≥65 years)+SC; elderly (≥65) without SC or younger (<65)+SC; and younger (<65) without SC. NCCN Guidelines for CLL/SLL V.2.2017 were used, given 74% informCLL enrollment ≥2017. Results: In informCLL (N=1462; previously untreated [1L], 58%; relapsed/refractory [R/R], 42%), community-based practices enrolled 93%. Median age: 71 years (34–95); median CCI: 1.0 (0–11); CCI ≥3: 16%. 27% of patients (n=389) had del(17p)/TP53mut data available. 59%–64% with del(17p)/TP53mut and 68%–100% without del(17p)/TP53mut received NCCN-recommended regimens. For patients with del(17p)/TP53mut, 62% 1L and 44% R/R received recommended category-2A ibrutinib; 24% 1L and 21% R/R had non-recommended CIT (BR/FCR). For patients without del(17p)/TP53mut and frail+SC, 60% 1L had category-1 ibrutinib or obinutuzumab+chlorambucil, but 24% received non-recommended BR; all R/R patients had category-1 ibrutinib or idelalisib+rituximab. For patients without del(17p)/TP53mut and elderly/younger+SC, 69% 1L and 58% R/R patients had category-1 ibrutinib or category-2A BR. For patients without del(17p)/TP53mut and younger without SC, 87% 1L and 82% R/R had BR (category-2A), FCR (1L: category-1; R/R: category-2A), or ibrutinib (1L: category-2A; R/R: category-1). For patients without del(17p)/TP53mut data available (73%, n=1073), ibrutinib (44%), CIT (32%), and anti-CD20 monotherapy (14%) were the most common regimens. Conclusions: Of patients with del(17p)/TP53mut, one-third received non-NCCN-recommended regimens. Given most patients in informCLL lacked del(17p)/TP53mut data and may have received suboptimal therapy, there is a need for awareness of guidelines recommendations to better inform treatment decisions. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2017 - February 21, 2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed 08/08/2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. To evaluate how treatment regimens in informCLL aligned with NCCN Guidelines®-recommended regimens for CLL/SLL. Patients receiving approved CLL treatment were categorized by del(17p)/TP53 mutation status, line of therapy, and age/comorbidity. Significant comorbidities (SC) were defined as Charlson Comorbidity Index (CCI) ≥3. Age/comorbidity groups for patients without del(17p)/TP53mut: frail (≥65 years)+SC; elderly (≥65) without SC or younger (<65)+SC; and younger (<65) without SC. NCCN Guidelines for CLL/SLL V.2.2017 were used, given 74% informCLL enrollment ≥2017. In informCLL (N=1462; previously untreated [1L], 58%; relapsed/refractory [R/R], 42%), community-based practices enrolled 93%. Median age: 71 years (34–95); median CCI: 1.0 (0–11); CCI ≥3: 16%. 27% of patients (n=389) had del(17p)/TP53mut data available. 59%–64% with del(17p)/TP53mut and 68%–100% without del(17p)/TP53mut received NCCN-recommended regimens. For patients with del(17p)/TP53mut, 62% 1L and 44% R/R received recommended category-2A ibrutinib; 24% 1L and 21% R/R had non-recommended CIT (BR/FCR). For patients without del(17p)/TP53mut and frail+SC, 60% 1L had category-1 ibrutinib or obinutuzumab+chlorambucil, but 24% received non-recommended BR; all R/R patients had category-1 ibrutinib or idelalisib+rituximab. For patients without del(17p)/TP53mut and elderly/younger+SC, 69% 1L and 58% R/R patients had category-1 ibrutinib or category-2A BR. For patients without del(17p)/TP53mut and younger without SC, 87% 1L and 82% R/R had BR (category-2A), FCR (1L: category-1; R/R: category-2A), or ibrutinib (1L: category-2A; R/R: category-1). For patients without del(17p)/TP53mut data available (73%, n=1073), ibrutinib (44%), CIT (32%), and anti-CD20 monotherapy (14%) were the most common regimens. Of patients with del(17p)/TP53mut, one-third received non-NCCN-recommended regimens. Given most patients in informCLL lacked del(17p)/TP53mut data and may have received suboptimal therapy, there is a need for awareness of guidelines recommendations to better inform treatment decisions. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2017 - February 21, 2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed 08/08/2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way." @default.
• W3197340014 created "2021-09-13" @default.
• W3197340014 creator A5013007045 @default.
• W3197340014 creator A5014679739 @default.
• W3197340014 creator A5018677064 @default.
• W3197340014 creator A5026878298 @default.
• W3197340014 creator A5042332348 @default.
• W3197340014 creator A5044959368 @default.
• W3197340014 creator A5056116635 @default.
• W3197340014 creator A5070871199 @default.
• W3197340014 creator A5074766331 @default.
• W3197340014 creator A5075229974 @default.
• W3197340014 creator A5083072418 @default.
• W3197340014 date "2021-09-01" @default.
• W3197340014 modified "2023-09-27" @default.
• W3197340014 title "CLL-074: Insights From the informCLL Registry: Real-World Application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)" @default.
• W3197340014 doi "https://doi.org/10.1016/s2152-2650(21)01749-3" @default.
• W3197340014 hasPublicationYear "2021" @default.
• W3197340014 type Work @default.
• W3197340014 sameAs 3197340014 @default.
• W3197340014 citedByCount "1" @default.
• W3197340014 countsByYear W31973400142021 @default.
• W3197340014 crossrefType "journal-article" @default.
• W3197340014 hasAuthorship W3197340014A5013007045 @default.
• W3197340014 hasAuthorship W3197340014A5014679739 @default.
• W3197340014 hasAuthorship W3197340014A5018677064 @default.
• W3197340014 hasAuthorship W3197340014A5026878298 @default.
• W3197340014 hasAuthorship W3197340014A5042332348 @default.
• W3197340014 hasAuthorship W3197340014A5044959368 @default.
• W3197340014 hasAuthorship W3197340014A5056116635 @default.
• W3197340014 hasAuthorship W3197340014A5070871199 @default.
• W3197340014 hasAuthorship W3197340014A5074766331 @default.
• W3197340014 hasAuthorship W3197340014A5075229974 @default.
• W3197340014 hasAuthorship W3197340014A5083072418 @default.
• W3197340014 hasConcept C126322002 @default.
• W3197340014 hasConcept C143998085 @default.
• W3197340014 hasConcept C2777607594 @default.
• W3197340014 hasConcept C2777938653 @default.
• W3197340014 hasConcept C2778461978 @default.
• W3197340014 hasConcept C2779159551 @default.
• W3197340014 hasConcept C2779338263 @default.
• W3197340014 hasConcept C2779878957 @default.
• W3197340014 hasConcept C2780653079 @default.
• W3197340014 hasConcept C71924100 @default.
• W3197340014 hasConceptScore W3197340014C126322002 @default.
• W3197340014 hasConceptScore W3197340014C143998085 @default.
• W3197340014 hasConceptScore W3197340014C2777607594 @default.
• W3197340014 hasConceptScore W3197340014C2777938653 @default.
• W3197340014 hasConceptScore W3197340014C2778461978 @default.
• W3197340014 hasConceptScore W3197340014C2779159551 @default.
• W3197340014 hasConceptScore W3197340014C2779338263 @default.
• W3197340014 hasConceptScore W3197340014C2779878957 @default.
• W3197340014 hasConceptScore W3197340014C2780653079 @default.
• W3197340014 hasConceptScore W3197340014C71924100 @default.
• W3197340014 hasLocation W31973400141 @default.
• W3197340014 hasOpenAccess W3197340014 @default.
• W3197340014 hasPrimaryLocation W31973400141 @default.
• W3197340014 hasRelatedWork W1550739321 @default.
• W3197340014 hasRelatedWork W2106082064 @default.
• W3197340014 hasRelatedWork W2256822827 @default.
• W3197340014 hasRelatedWork W2606155555 @default.
• W3197340014 hasRelatedWork W2659965582 @default.
• W3197340014 hasRelatedWork W2902300122 @default.
• W3197340014 hasRelatedWork W2905243278 @default.
• W3197340014 hasRelatedWork W3029558579 @default.
• W3197340014 hasRelatedWork W4312948978 @default.
• W3197340014 hasRelatedWork W2912615048 @default.
• W3197340014 hasVolume "21" @default.
• W3197340014 isParatext "false" @default.
• W3197340014 isRetracted "false" @default.
• W3197340014 magId "3197340014" @default.
• W3197340014 workType "article" @default.